Niemann Pick Diseases
Conditions
Keywords
Eye Movement, Niemann Pick C
Brief summary
This study is done in conjunction with a trial, conducted at Columbia University College of Physicians and Surgeons in New York and the Royal Manchester Children's Hospital in England, to examine the effectiveness of a new drug called OGT 918 for treating Niemann-Pick Type C (NPC) disease. Patients with this genetic disorder do not transport lipids (fatty substances) in their cells, resulting in problems of the liver, spleen and brain. An early sign of NPC is a reduced ability to move the eyes rapidly up and down or from side to side. These voluntary eye movements are called saccades. Patients in the OGT 918 trial who participate in this sub-study will have their saccadic eye movements measured to see if improvement occurs with OGT 918 treatment. Patients with Niemann-Pick Type C disease 12 years of age and older who are enrolled in the OGT 918 trial described above may be eligible for this study. Participants will have both vertical (up and down) and horizontal (side to side) saccadic eye movements measured at two time points before starting treatment with OGT 918 and after 12 months of treatment. For the test, patients sit in a chair with their head positioned as for a regular eye examination (steadied by a chin cup and headrest) and follow with their eyes a series of lights or laser spots moving on a screen at a distance of 1 meter (3 feet). During the test, patients wear either special recording glasses, infrared goggles, or special contact lenses for measuring eye movements. A full eye evaluation lasts about 1 hour, and each eye is evaluated twice. The evaluations are separated in time by at least an hour, and possibly a day.
Detailed description
None given, verified by PI.
Interventions
DRUGOGT918
Sponsors
National Eye Institute (NEI)
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: Patients with NPC disease confirmed by abnormal cholesterol esterification and abnormal filipin staining. Patients aged 12 and over. Body weight must not be less than 14 kg. Patients who can ingest a capsule.
Exclusion criteria
Patients younger than 18 who are unable to give informed assent and/or whose legal guardian is unable to provide informed consent. Patients aged 18 and over who cannot provide informed consent and/or whose legal guardian is unable to provide witnessed informed consent. Fertile patients who do not agree to use adequate contraception throughout the study and for three months after cessation of OGT 918 treatment. Patients who cannot tolerate the study procedures or who are unable to travel to the study center as required by this protocol. Patients currently undergoing therapy with other investigational agents or patients taking drugs or food supplements which may interfere with gastrointestinal absorption or motility. Patients suffering from clinically significant diarrhoea (greater than 3 liquid stools per day for greater than 7 days) without definable cause within 3 months of Screening Visit, or who have a history of significant gastrointestinal disorders. Patients with an intercurrent medical condition that would render them unsuitable for the study e.g. HIV, hepatitis infection. Patients who in the opinion of the investigator (for whatever reason) are thought to be unsuitable for the study.
Countries
United Kingdom, United States
Outcome results
None listed